Finally, the relevance of ZFP62–artenimol and the ongoing research on NADH’s role in treating severe COVID-19 symptoms implies that the other predicted drug–target interaction, ZNF286A targeted by NADH, may also be relevant for COVID-19. This evidence concerns the gene ZNF286A and COVID-19.